Citadel Advisors
SMMT icon

Citadel Advisors’s Summit Therapeutics SMMT Stock Holding History

Citadel Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.1M Buy
1,725,716
+1,283,973
+291% +$22.8M ﹤0.01% 2291
2026
Q1 		$8.38M Sell
441,743
-2,033,965
-82% -$32.9M ﹤0.01% 3504
2025
Q4 		$43.3M Buy
2,475,708
+2,272,996
+1,121% +$42.8M 0.01% 1555
2025
Q3 		$4.19M Buy
202,712
+100,295
+98% +$2.43M ﹤0.01% 4678
2025
Q2 		$2.18M Sell
102,417
-896,323
-90% -$20.4M ﹤0.01% 5548
2025
Q1 		$19.3M Buy
998,740
+811,333
+433% +$16.3M ﹤0.01% 2084
2024
Q4 		$3.34M Sell
187,407
-463,426
-71% -$8.98M ﹤0.01% 4655
2024
Q3 		$14.3M Buy
+650,833
New +$9.1M ﹤0.01% 2437
2024
Q2 		– Sell
-5
Closed -$27 – 15304
2024
Q1 		$21 Buy
+5
New +$20 ﹤0.01% 14453
2023
Q2 		– Sell
-22,381
Closed -$39.2K – 15149
2023
Q1 		$39.2K Sell
22,381
-25,997
-54% -$70.9K ﹤0.01% 12453
2022
Q4 		$206K Buy
+48,378
New +$88K ﹤0.01% 10088
2022
Q3 		– Sell
-56,743
Closed -$64.2K – 13535
2022
Q2 		$57K Buy
+56,743
New +$79.5K ﹤0.01% 11849
2022
Q1 		– Sell
-42,593
Closed -$107K – 14497
2021
Q4 		$115K Buy
+42,593
New +$205K ﹤0.01% 12577
2021
Q3 		– Sell
-25,618
Closed -$184K – 14583
2021
Q2 		$191K Sell
25,618
-16,973
-40% -$111K ﹤0.01% 12216
2021
Q1 		$250K Buy
42,591
+26,421
+163% +$170K ﹤0.01% 11233
2020
Q4 		$76K Buy
+16,170
New +$68.5K ﹤0.01% 10370
2019
Q2 		– Sell
-23,783
Closed -$44K – 9790
2019
Q1 		$44K Buy
23,783
+5,782
+32% +$9.48K ﹤0.01% 8875
2018
Q4 		$21K Buy
+18,001
New +$28K ﹤0.01% 8736

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Citadel Advisors's SMMT Position: Q2 2026 in Review

Citadel Advisors increased its Summit Therapeutics (SMMT) stake by 291% in Q2 2026, buying an estimated $22.8M and bringing the position to 1,725,716 shares worth $25.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2291.

Citadel Advisors first reported a position in SMMT in Q4 2018 and has held it in 18 quarters since. The position peaked at $43.3M in Q4 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Citadel Advisors held 1,725,716 shares of Summit Therapeutics worth $25.1M as of Q2 2026.
  • Citadel Advisors bought 1,283,973 Summit Therapeutics shares in Q2 2026, an estimated $22.8M.
  • Summit Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2291 holding.
  • Citadel Advisors first reported a position in Summit Therapeutics in Q4 2018 and has held it in 18 quarters since.
  • Citadel Advisors's Summit Therapeutics position peaked at $43.3M in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.